Patients with relapsing multiple sclerosis (MS) treated with intravenous ublituximab had fewer relapses and brain lesions compared with those treated with oral teriflunomide, although both therapies […]
To expand therapy options, availability, and access, FDA is: Expanding availability and access to evidence-based treatments for substance use disorders Facilitating development of treatments for substance […]
To reduce morbidity and mortality associated with overdoses, FDA is: Expanding availability and access to overdose reversal products, including naloxone, by supporting accelerated review of products […]
To eliminate unnecessary initial exposure and inappropriate prolonged prescribing of substances with abuse potential, FDA is: Promoting appropriate prescribing of medications with abuse potential, including opioids, […]
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.